Abstract:Background: Current hypertension guidelines recommend combination of an angiotensin-converting enzyme inhibitor or angiotensin-receptor blocker with a calcium-channel blocker or thiazide diuretic as initial antihypertensive therapy in patients with monotherapy uncontrolled hypertension. However, to what extent these two different combinations are comparable in blood pressure (BP)-lowering efficacy and safety remains under investigation, especially in the Chinese population. We investigated the BP-lowering efficacy and safety of the amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies in Chinese patients. Methods: In a multi-center, randomized, actively controlled, parallel-group trial, we enrolled patients with stage 1 or 2 hypertension from July 2018 to June 2021 in 20 hospitals and community health centers across China. Of the 894 screened patients, 560 eligible patients were randomly assigned to amlodipine/benazepril 5/10 mg (n = 282) or benazepril/hydrochlorothiazide 10/12.5 mg (n = 278), with 213 and 212 patients, respectively, who completed the study and had a valid repeat ambulatory BP recording during follow-up and were included in the efficacy analysis. The primary outcome was the change from baseline to 24 weeks of treatment in 24-h ambulatory systolic BP. Adverse events including symptoms and clinically significant changes in physical examinations and laboratory findings were recorded for safety analysis. Results: In the efficacy analysis (n = 425), the primary outcome, 24-h ambulatory systolic BP reduction, was - 13.8 ± 1.2 mmHg in the amlodipine/benazepril group and - 12.3 ± 1.2 mmHg in the benazepril/hydrochlorothiazide group, with a between-group difference of - 1.51 (p = 0.36) mmHg. The between-group differences for major secondary outcomes were - 1.47 (p = 0.18) in 24-h diastolic BP, - 2.86 (p = 0.13) and - 2.74 (p = 0.03) in daytime systolic and diastolic BP, and - 0.45 (p = 0.82) and - 0.93 (p = 0.44) in nighttime systolic and diastolic BP. In the safety analysis (n = 560), the incidence rate of dry cough was significantly lower in the amlodipine/benazepril group than in the benazepril/hydrochlorothiazide group (5.3% vs 10.1%, p = 0.04). Conclusions: The amlodipine/benazepril and benazepril/hydrochlorothiazide dual therapies were comparable in ambulatory systolic BP lowering. The former combination, compared with the latter, had a greater BP-lowering effect in the daytime and a lower incidence rate of dry cough. Trial registration: ClinicalTrials.gov, NCT03682692. Registered on 18 September 2018.

E0352 Efficacy and Safety of Aliskiren in Chinese Patients with Mild or Moderate Essential Hypertension

Efficacy and Safety of Aliskiren, a Direct Renin Inhibitor, Compared with Ramipril in Asian Patients with Mild to Moderate Hypertension

Aliskiren Therapy in Hypertension and Cardiovascular Disease: a Systematic Review and a Meta-Analysis

Effect of Aliskiren on Arterial Stiffness, Compared with Ramipril in Patients with Mild to Moderate Essential Hypertension.

Efficacy and Safety of Sacubitril/Allisartan for the Treatment of Primary Hypertension

Aliskiren-Attenuated Myocardium Apoptosis Via Regulation of Autophagy and Connexin-43 in Aged Spontaneously Hypertensive Rats

Efficacy and Safety of the Compound of Candesartan Cilexetial and Hydrochlorothiazide in Patients with Essential Hypertension

[A Randomized, Double-Blind, Double-Dummy Study Comparing a Fixed Dose Combination of Telmisartan 80 Mg Plus Hydrochlorothiazide 12.5 Mg to Telmisartan 80 Mg in Chinese Hypertensive Patients Who Failed to Respond Adequately to Telmisartan 80 Mg].

PS 17-77 A RANDOMIZED, DOUBLE-BLIND AND DOUBLE-DUMMY, MULTIPLE-DOSE, POSITIVE AND PARALLEL COMPARATIVE, MULTICENTER CLINICAL TRIAL OF ALLISARTAN EVALUATE EFFICACY AND SAFETY IN PATIENTS WITH MILD TO MODERATE ESSENTIAL HYPERTENSION

Efficacy Comparison Between 5 Mg Perindopril Arginine Salt and 4 Mg Perindopril Tert-Butylamine Salt for Patients with Mild to Moderate Essential Hypertension

Aliskiren Vs. Other Antihypertensive Drugs in the Treatment of Hypertension: a Meta-Analysis

P.3.a.008 Efficacy and Safety of Long-Acting Risperidone Injection after Switching from Antipsychotics in Chinese Patients

A Multicentre Study of the Safety of Ramiprill in High-Risk Cardiovascular Patients

Efficacy and Safety of Olmesartan Medoxomil-Amlodipine Besylate Tablet in Chinese Patients with Essential Hypertension: A Prospective, Single-Arm, Multi-Center, Real-World Study

Efficacy and Safety of Renal Denervation for Chinese Patients with Resistant Hypertension Using a Microirrigated Catheter: Study Design and Protocol for a Prospective Multicentre Randomised Controlled Trial

Efficacy and Safety of Olmesartan Medoxomil‑amlodipine Besylate Tablets (sevikar®) in Older Patients with Essential Hypertension: Subgroup Analysis from the Sevikar Study.

Efficacy and Safety of Sacubitril/valsartan Compared with Olmesartan in Asian Patients with Essential Hypertension: A Randomized, Double-Blind, 8-Week Study.

[Efficacy and Safety of Olmesartan Medoxomil Versus Losartan Potassium in Chinese Patients with Mild to Moderate Essential Hypertension].

Comparison of two single-pill dual combination antihypertensive therapies in Chinese patients: a randomized, controlled trial

Efficacy and safety evaluation of Allisartan Isoproxil in patients with hypertension: a meta-analysis

The Clinical Efficacy and Safety of Valsartan in Treatment of Patients with Essential Hypertensive